Recruiting
Phase 2

Inobrodib, Pomalidomide, Dexamethasone

Sponsor:

CellCentric Ltd.

Code:

NCT07096778

Conditions

Multiple Myeloma Refractory

Multiple Myeloma in Relapse

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Inobrodib

Pomalidomide

Dexamethasone

Study Details

Brief summary:

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Conditions

Multiple Myeloma Refractory

Multiple Myeloma in Relapse

Study ID

NCT07096778

Start date

Jan 22, 2026

Status verified date

Jul, 2026

Completion date

Dec 1, 2029

Anticipated

Primary completion date

Dec 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female ≥18 years of age
  • Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
  • Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate hematological, renal and hepatic function
  • Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners

Exclusion Criteria:

  • Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
  • Prior treatment with p300/CBP bromodomain inhibitors
  • Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
  • Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
  • Major surgery within 4 weeks of the first dose of study treatment
  • Live vaccine within 4 weeks of study treatment
  • Active or unresolved adverse events
  • Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
  • Female patients who are pregnant or breast-feeding at any time during the study
  • Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Inobrodib in combination with pomalidomide and dexamethasone

Interventions

Inobrodib

20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.

Pomalidomide

4 mg orally once daily on Day 1 to 21 of each 28-day cycle

Dexamethasone

40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

Primary outcome measure

  • Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC) [ Time Frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months) ]

Central Contacts and Locations

Central contacts

CCS1477-04 Clinical Operations

+44 1799 531130DOMMINO-1@cellcentric.com

Locations

Mayo Clinic Arizona

Recruiting

Phoenix, Arizona, United States, 85054

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Mayo Clinic Florida

Recruiting

Jacksonville, Florida, United States, 32224

H Lee Moffitt Cancer Center & Research Institute

Recruiting

Tampa, Florida, United States, 33612

Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

University of Chicago Medical Center

Recruiting

Chicago, Illinois, United States, 60637

American Oncology Partners, PA

Recruiting

Bethesda, Maryland, United States, 20817

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

University of Nebraska Medical Center

Recruiting

Omaha, Nebraska, United States, 68198

John Theurer Cancer Center at Hackensack University Medical Center

Recruiting

Hackensack, New Jersey, United States, 07601

Rutgers Cancer Institute of New Jersey

Recruiting

New Brunswick, New Jersey, United States, 08901

Levine Cancer Institute

Recruiting

Charlotte, North Carolina, United States, 28204

Wake Forest University Health Sciences

Recruiting

Winston-Salem, North Carolina, United States, 27157

Cleveland Clinic

Recruiting

Cleveland, Ohio, United States, 44195

University of Pennsylvania, Abramson Cancer Center

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Fred Hutchinson Cancer Center

Recruiting

Seattle, Washington, United States, 98109

Froedtert Hospital & the Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

More Information

Sponsor

CellCentric Ltd.

Last update posted

Jul 30, 2026

Last verified

Jul, 2026

Keywords

  • Inobrodib
  • Pomalidomide
  • Pomalyst
  • Imnovid
  • Dexamethasone
  • p300-CBP Transcription Factors

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by CellCentric Ltd. on 2026-07-30.